Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates - Wikidata - awgldk - TriplyDB

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

http://www.wikidata.org/entity/Q33406591

about

Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends Management of recurrent hepatocellular carcinoma after liver transplant Combination treatment including targeted therapy for advanced hepatocellular carcinoma Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives.Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives.Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.Sorafenib use in the transplant setting.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Advanced Hepatocellular Cancer: the Current State of Future Research.mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.The role of mTOR inhibitors in the treatment of hepatocellular carcinoma.Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

P2860

Q26830194-CE7D5105-5EDF-4241-915A-625D19F26E59 Q26997063-328F29E9-BDED-42C8-BF47-6345C9E289D0 Q28077738-15BE4FB0-3056-4653-9498-EC661889EB64 Q33422744-D4A1F90B-93AD-424E-8068-9DA545CB3645 Q33904328-7331DC98-01F4-48CD-98CE-CB325FB3AE67 Q35231826-F3A60BA5-53C6-49F5-BFB4-F6FBB678CF7E Q35440625-998AFDA5-81E7-4163-A667-4990E55035DD Q36270115-2DFFABD7-B463-4F44-B97B-09BD4F059D19 Q36273796-330F31D0-521A-41AC-9F73-CAD4DB79586A Q36998239-AFBA53D6-1F07-4CCF-BB9C-E4786D9C6D7C Q37031712-E5A3DF7B-F01D-4BA4-AD3D-89D7969CC1AE Q37581334-CCFC7E92-B52F-40D7-8F70-DA671D6F6764 Q37694481-83EDC93E-2BB5-4C8A-AAB7-7411298E2514 Q37722656-6C611865-CD6E-487F-AB7B-403FC2710346 Q38201707-D25E1B6C-20B6-4A7B-A729-FAE16DD3D810 Q38210270-3D20C9DB-657C-49EC-A0F1-FD60CCC5D7FF Q38242086-2BE4F487-410B-442B-9CAC-9E872B59D0FD Q38635603-F6AB463F-B542-4BF8-93DB-2F2A92731561 Q38848537-428155B9-082B-4471-B24D-75DB588FA6C1 Q41233635-BB1BFDEE-F12E-4EBD-AE9C-CE1FA3EA73D2 Q41547474-7FAEBF38-53B2-46B6-9416-3DEF66307FCD Q42703579-68AA23B5-5928-4C32-8C9A-000ADE9BB7D8 Q44930012-2F7C3506-2D88-4C29-8CDA-88924A3FA1C4 Q45848255-DA23381E-9CE2-44C2-BD7B-9FFCEF68EE78 Q47219387-6762D84C-1068-45A5-A9DE-36BE0D942955

P2860

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

http://www.wikidata.org/entity/Q33406591

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Temsirolimus combined with sor ...... netic and biomarker correlates

@ast

Temsirolimus combined with sor ...... netic and biomarker correlates

@en

type

label

Temsirolimus combined with sor ...... netic and biomarker correlates

@ast

Temsirolimus combined with sor ...... netic and biomarker correlates

@en

prefLabel

Temsirolimus combined with sor ...... netic and biomarker correlates

@ast

Temsirolimus combined with sor ...... netic and biomarker correlates

@en

P1433

Q33406591-2405E786-1D40-47C8-96E2-4AA54B46E787

P1476

Q33406591-6174BE13-B316-4E6A-A6D2-7B4AC5BCBA5E

P2093

Q33406591-1E5AF304-90BB-45BE-B37C-3CE59F4194A0

Q33406591-4CEFEEF2-ABBB-43C6-8568-C5F5098C6BD6

Q33406591-4E76EF2D-6BAE-44BF-8378-7C386661600B

Q33406591-59D5261B-09B4-4634-A97F-E5ABF0CC1CD7

Q33406591-6949F216-2AE5-43AB-B937-123C0BE1E55F

Q33406591-7254EDD5-3799-4753-A085-7B189375B5B7

Q33406591-8B3582FD-7E51-4805-A2CA-FCAF7D26F473

Q33406591-93020C3E-5F12-4F0E-A5BF-67360A386BE1

Q33406591-A74E7876-4D57-4958-AB83-78793C765827

Q33406591-ABA8EEF7-16A2-4745-8450-13228E0FC15C

P2860

Q33406591-0480239A-AFA8-4332-AC09-487DE757B735

Q33406591-0CCEB7E5-B2A5-464E-AAF7-816E10F63D40

Q33406591-1101A7AB-9995-4D68-8336-93BEED23A32E

Q33406591-125AF07F-0121-4E9E-8210-B0F491DEBE29

Q33406591-197894D8-89D2-4011-A8AC-7DD7D7817095

Q33406591-1DB585AC-7434-4F88-AEF5-BD9B41990EBE

Q33406591-1DF59A84-264F-451B-B469-F2EE680A6C6C

Q33406591-27F8F5A3-3CCD-4875-A01C-BF7D382E0870

Q33406591-2D3A90C7-3505-4FF2-97F0-B105F4963DE0

Q33406591-2F217FC4-4E85-44B5-863C-FFEC3AE90E5B

P304

Q33406591-1B4E9335-3145-45A8-80E5-2C58F2FA40C4

P31

Q33406591-54B64818-6530-4EE1-B380-A7582584BBAA

P356

Q33406591-C18F3799-F0C4-4465-9CB5-F6313B27B5C9

P433

Q33406591-6584EF1B-3A4B-4FE1-B387-BD0A3CFC0319

P478

Q33406591-52A20BC9-1453-4682-95DE-C656548986F0

P577

Q33406591-B0A37F54-16DA-416B-A4EE-76AD1DC5CF33

P5875

Q33406591-93D9FD3C-7D19-407D-BA98-1D197938A0B3

P698

Q33406591-5509B4D6-533C-4FF3-8E6E-AF406AACCAD8

P921

Q33406591-BE73B9B4-6856-4F33-B3A5-F7BB9DA22DA8

Q33406591-E73ED123-F001-4251-A9E6-A20FE5FA2AD4

P932

Q33406591-1981B560-EB12-48F1-A25B-DD732E9FCCE2

P356

P1433

Annals of Oncology

P1476

Temsirolimus combined with sor ...... netic and biomarker correlates

@en

P2093

A B Benson

http://www.w3.org/2001/XMLSchema#string

A H Ko

http://www.w3.org/2001/XMLSchema#string

A P Venook

http://www.w3.org/2001/XMLSchema#string

B M Yeh

http://www.w3.org/2001/XMLSchema#string

C-M Li

http://www.w3.org/2001/XMLSchema#string

E K Bergsland

http://www.w3.org/2001/XMLSchema#string

H S Nimeiri

http://www.w3.org/2001/XMLSchema#string

J A Grabowsky

http://www.w3.org/2001/XMLSchema#string

J Hwang

http://www.w3.org/2001/XMLSchema#string

L Stucky-Marshall

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.

P304

1900-1907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDT109

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236071931

http://www.w3.org/2001/XMLSchema#string

P698

23519998

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3690907

http://www.w3.org/2001/XMLSchema#string